Analysis Tools
normal phenotype
 |
• uninduced mice are normal and fertile
|
|
Allele Symbol Allele Name Allele ID |
Tsixtm1.1Awu targeted mutation 1.1, Anton Wutz MGI:5285833 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• uninduced mice are normal and fertile
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• uninduced mice are normal and fertile
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E0.5 exhibit severe developmental defect at E7.5 compared with control mice
• however, no developmental defect is observed when the allele is maternally inherited or when doxycycline treated blastocysts with paternally inherited Tsixtm1.1Awu are transplanted into wild-type recipients
|
|
|
• when Tsixtm1.1Awu is inherited maternally, female mice treated with doxycycline from E6.5 exhibit reduced density of fetal capillaries in the placental labyrinth compared with control mice
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit a severe defect in fetal capillaries compared with control mice
|
|
|
• in severely affected female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• at E13.5 in female mice treated with doxycycline from E6.5 or E7.5 when Tsixtm1.1Awu is inherited paternally
• mild at E13.5 in female mice treated with doxycycline from E8.5 when Tsixtm1.1Awu is inherited paternally
• however, female mice treated with doxycycline from E9.5 exhibit normal placenta size at E13.5 when the allele is inherited paternally
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit a severe defect in all trophoblast cell types compared with control mice
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit overabundant and massively enlarged compared to in control mice
|
|
|
• in severely affected female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• absent in severely affected female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• increased in female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• in female mice treated with doxycycline from E6.5 when Tsixtm1.1Awu is inherited paternally
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E0.5 fail to imprint and inactivated the paternal X chromosome unlike in control mice
|
|
|
• when Tsixtm1.1Awu is inherited maternally, female mice treated with doxycycline from E6.5 exhibit reduced density of fetal capillaries in the placental labyrinth compared with control mice
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E6.5 exhibit a severe defect in fetal capillaries compared with control mice
|
|
|
• when Tsixtm1.1Awu is inherited paternally, female mice treated with doxycycline from E0.5 exhibit severe developmental defect at E7.5 compared with control mice
• however, no developmental defect is observed when the allele is maternally inherited or when doxycycline treated blastocysts with paternally inherited Tsixtm1.1Awu are transplanted into wild-type recipients
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/30/2024 MGI 6.23 |
|
|
|
||